Explore

Trendline Trendline
IDEAYA Biosciences Closes Public Offering, Raises $345 Million

IDEAYA Biosciences Closes Public Offering, Raises $345 Million

IDEAYA Biosciences Closes Public Offering, Raises $345 Million
Trendline Trendline
IDEAYA Biosciences Announces $300 Million Public Offering to Expand Precision Oncology Efforts

IDEAYA Biosciences Announces $300 Million Public Offering to Expand Precision Oncology Efforts

IDEAYA Biosciences Announces $300 Million Public Offering to Expand Precision Oncology Efforts
Trendline Trendline
IDEAYA Biosciences Announces $300 Million Public Offering to Advance Cancer Therapies

IDEAYA Biosciences Announces $300 Million Public Offering to Advance Cancer Therapies

IDEAYA Biosciences Announces $300 Million Public Offering to Advance Cancer Therapies
Trendline Trendline
Gross Law Firm Alerts ABIVAX Shareholders to Class Action Deadline Amid Stock Plunge

Gross Law Firm Alerts ABIVAX Shareholders to Class Action Deadline Amid Stock Plunge

Gross Law Firm Alerts ABIVAX Shareholders to Class Action Deadline Amid Stock Plunge
Trendline Trendline
Parabilis Sets Record with $670 Million IPO, Boosting Biotech Sector

Parabilis Sets Record with $670 Million IPO, Boosting Biotech Sector

Parabilis Sets Record with $670 Million IPO, Boosting Biotech Sector
Trendline Trendline
Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Innovative Platform

Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Innovative Platform

Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Innovative Platform
Trendline Trendline
Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Oncology Pipeline

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Oncology Pipeline

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Oncology Pipeline
Trendline Trendline
Boehringer Ingelheim Advances in HER-2 Positive Lung Cancer Treatment at ASCO 2026

Boehringer Ingelheim Advances in HER-2 Positive Lung Cancer Treatment at ASCO 2026

Boehringer Ingelheim Advances in HER-2 Positive Lung Cancer Treatment at ASCO 2026
Trendline Trendline
IDEAYA Biosciences Announces $300 Million Public Offering to Fund Cancer Therapy Development

IDEAYA Biosciences Announces $300 Million Public Offering to Fund Cancer Therapy Development

IDEAYA Biosciences Announces $300 Million Public Offering to Fund Cancer Therapy Development
Trendline Trendline
IDEAYA Biosciences Announces $300 Million Stock Offering to Fund Cancer Therapy Development

IDEAYA Biosciences Announces $300 Million Stock Offering to Fund Cancer Therapy Development

IDEAYA Biosciences Announces $300 Million Stock Offering to Fund Cancer Therapy Development
Trendline Trendline
Faruqi Faruqi, LLP Alerts Grail Investors of Class Action Deadline Amid Trial Results

Faruqi Faruqi, LLP Alerts Grail Investors of Class Action Deadline Amid Trial Results

Faruqi Faruqi, LLP Alerts Grail Investors of Class Action Deadline Amid Trial Results
Trendline Trendline
Tango and Revolution Medicines' Pancreatic Cancer Treatment Shows 92% Response Rate

Tango and Revolution Medicines' Pancreatic Cancer Treatment Shows 92% Response Rate

Tango and Revolution Medicines' Pancreatic Cancer Treatment Shows 92% Response Rate